Cargando…

PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples

BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Möller, Katharina, Knöll, Madeleine, Bady, Elena, Schmerder, Max Jonathan, Rico, Sebastian Dwertmann, Kluth, Martina, Hube-Magg, Claudia, Blessin, Niclas C., Mandelkow, Tim, Lennartz, Maximilian, Menz, Anne, Luebke, Andreas M., Höflmayer, Doris, Fraune, Christoph, Bernreuther, Christian, Lebok, Patrick, Uhlig, Ria, Contreras, Hendrina, Weidemann, Sören, Gorbokon, Natalia, Jacobsen, Frank, Clauditz, Till S., Steurer, Stefan, Burandt, Eike, Minner, Sarah, Sauter, Guido, Simon, Ronald, Marx, Andreas H., Krech, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986704/
https://www.ncbi.nlm.nih.gov/pubmed/36683495
http://dx.doi.org/10.3233/CBM-220030
Descripción
Sumario:BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin’s lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma ([Formula: see text] 0.0001 each). CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.